Funding

Turn ideas into impact

Viewing all 918 opportunities
Filter Options
918 results :
Filter List
Close
Update Filters
1
Type
Amount
Source
Eligibility
Status
View 918 Results
Clear All Filters

Due: October 25, 2027

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)

Type

Cooperative Agreement

Source

Federal

Opp Number

PAR-25-352

Due: October 25, 2027

Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)

Type

Cooperative Agreement

Source

Federal

Opp Number

PAR-25-103

Due: October 25, 2027

Cancer Prevention and Control Clinical Trials Planning Grant Program(R34 Clinical Trials Optional)

US $600,000

Type

Grant

Source

Federal

Due: October 25, 2027

Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)

US $600,000

Type

Grant

Source

Federal

Due: October 25, 2027

Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)

Type

Grant

Source

Federal

Opp Number

PAR-25-104

Due: November 5, 2027

Limited Competition: Renewal of Existing NINDS-Supported Clinical Trial Cooperative Agreement Awards (U01 – Clinical Trials Required)

Type

Cooperative Agreement

Source

Federal

Opp Number

PAR-25-149

Due: November 5, 2027

Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional)

US $1,500,000

Type

Cooperative Agreement

Source

Federal

Opp Number

PAR-25-297

Due: November 5, 2027

Research on Current Topics in Alzheimer’s Disease and Its Related Dementias (R01 Clinical Trial Optional)

Type

Grant

Source

Federal

Opp Number

PAR-25-332

Due: November 8, 2027

BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)

Type

Grant

Source

Federal

Opp Number

RFA-DA-27-004

Submit your funding opportunity.

Do you have a grant, incentive, funding competition, or other funding source to share?

Next up:

Facilities